CN1204895C - Etoposide enteric slow (controlled) release solid dispersing preparation and its preparation method - Google Patents
Etoposide enteric slow (controlled) release solid dispersing preparation and its preparation method Download PDFInfo
- Publication number
- CN1204895C CN1204895C CN 02153962 CN02153962A CN1204895C CN 1204895 C CN1204895 C CN 1204895C CN 02153962 CN02153962 CN 02153962 CN 02153962 A CN02153962 A CN 02153962A CN 1204895 C CN1204895 C CN 1204895C
- Authority
- CN
- China
- Prior art keywords
- mentioned
- etoposide
- control
- micropill
- slow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to an etoposide enteric slow (controlled) release solid dispersing medicinal composition which comprises 5 to 30 wt% of etoposide, 5 to 50 wt % of solid dispersing carrier, 3 to 35 wt% of slow (controlled) release material and pharmaceutically acceptable medicinal adjuvants as other components. The medicinal composition also comprises an enteric soluble film forming material and has the dosage forms of tablets and hard capsules. Pharmacodynamics experiments, safety experiments and pharmacokinetics experiments prove that the medicinal composition of the present invention has the advantages of good clinical curative effect, low toxic and side reaction, and high oral bioavailability.
Description
Technical field:
The enteric slow (control) that the present invention relates to a kind of pharmaceutical composition that contains etoposide and preparation method thereof, particularly etoposide is released solid dispersed formulation and preparation method thereof.
Background technology:
Etoposide is a kind of Cytotoxic broad-spectrum anti-tumor medicine, there are two big characteristics its pharmacokinetics aspect: 1, because etoposide is reversible with combining of topoisomerase II, and act on long-term S phase and G2 phase in the cell cycle, therefore the length of blood drug level persistent period is just bigger to the influence of drug effect than peak concentration, be that comparatively outstanding time dependence medicine is [referring to Cavalli F, Sonntag RW, Jung F, et al.VP-16-213monotherapy for remission induction of small cell lung cancer:a randomized trialusing three dosage schedules.Cancer Treat Rep, 1978,62:473], when plasma concentration at 1～3mgL
-1The time, cellulotoxic effect is better, and bone marrow toxicity is also lighter, as plasma concentration＞5mgL
-1The time, antitumous effect increases not obvious, and bone marrow toxicity obviously strengthens [referring to Wolff SN, Grosh WW, Prater K, et al.In vitropharmacodynamic evaluation of VP-16-213 and implications for chemotherapy.CancerChemother Pharmacol.1987,19:246].At present, being used for clinical etoposide has two kinds of dosage forms, i.e. injection and oral soft capsule agent.Injection uses inconvenience, cost height; The dissolubility extreme difference of etoposide, and its degraded easily under the effect of gastric acid so the oral soft capsule preparation bioavailability of prior art is low, only are 25%-74%.For increasing the persistent period of effective blood drug concentration, number of times is taken in the dosage or the increase that need to increase oral soft capsule, but can cause toxic and side effects to increase like this.
Summary of the invention:
The technical problem to be solved in the present invention is the toxicity of development reduction etoposide, the toleration of increase treatment, and then improves the oral formulations of its antitumor curative effect.
The invention provides a kind of etoposide enteric slow (control) and release the solid dispersion medicine compositions.
Contain etoposide 5～30% (weight), solid dispersion carrier 5～50% (weight) in the pharmaceutical composition of the present invention, slow (control) releases material 3～35% (weight), other composition is pharmaceutically acceptable pharmaceutical adjuvant.
Contained solid dispersion carrier is one or more in acceptable water-solubility carrier or water insoluble carrier or the enteric solubility carrier pharmaceutically in the pharmaceutical composition of the present invention.
Described water-solubility carrier is selected from Macrogol 4000, polyethylene glycol 6000, cetomacrogol 1000 0, polyethylene pyrrole Lip river alkane ketone, Pluromic F68, carbamide, citric acid, succinic acid, dextran, galactose, sucrose and mannitol, preferred polyethylene glycol 6000, polyethylene pyrrole Lip river alkane ketone, Pluromic F68.
Described water insoluble carrier is selected from ethyl cellulose, polyacrylic resin, cholesterol, tripalmitin, cholesterol ester stearic acid, Brazil wax, preferred, ethyl.
Described enteric solubility carrier is selected from Hydroxypropyl Methylcellulose Phathalate or polyacrylic resin, the optimization polypropylene acid resin.
Slow (control) in the pharmaceutical composition of the present invention released material and comprised that matrix type slow (control) is released material and film controlling type slow (control) is released material.
Described matrix type slow (control) is released material and is selected from insoluble framework material, bioerodable framework material and hydrophilic gel matrix material.
Described insoluble framework material is selected from ethyl cellulose, polyethylene, polypropylene, polysiloxanes, ethylene-acetate ethylene copolymer and polymethyl methacrylate, preferred, ethyl.
Described bioerodable framework material is selected from stearic acid, Brazil wax, glyceryl monostearate, stearyl alcohol and acrylic resin, preferred acrylic resins.
Described hydrophilic gel matrix material is selected from sodium alginate, hydroxypropyl emthylcellulose, takes off the fine chitin of second, polyvinyl alcohol, preferred sodium alginate or hydroxypropyl emthylcellulose.
Described film controlling type slow (control) is released material and is selected from ethyl cellulose class or polyacrylic resin class.
Described ethyl cellulose comprises Aquacoat.
Described polyacrylic resin class is selected from butyl methacrylate, Dimethylaminoethyl Methacrylate and methylmethacrylate copolymer, methacrylic acid and ethyl acrylate copolymer, methacrylic acid and methylmethacrylate copolymer, ethyl acrylate, methyl methacrylate and methacrylic acid chlorination trimethylamine groups ethyl ester copolymer, ethyl acrylate and methylmethacrylate copolymer are preferably ethyl acrylate, the aqueous dispersion of methyl methacrylate and methacrylic acid chlorination trimethylamine groups ethyl ester copolymer and the aqueous dispersion of ethyl acrylate and methylmethacrylate copolymer.
Pharmaceutical composition of the present invention also can include the enteric solubility filmogen, is coated on the surface that micropill (capsule filling) released in slow (control) release tablet formulations or slow (control).
Described enteric solubility material is selected from methacrylic acid and ethyl acrylate copolymer, methacrylic acid and methylmethacrylate copolymer, is preferably the aqueous dispersion of methacrylic acid and methylmethacrylate copolymer.
Pharmaceutical composition of the present invention also comprises enteric coated preparation well known in the art and slow (control) release formulation adjuvant commonly used.
The dosage form of pharmaceutical composition of the present invention is tablet and capsule, comprises two kinds of film controlling type and matrix types.Described capsule can be common hard capsule or enteric solubility hard capsule.
Pharmaceutical composition of the present invention adopts solid dispersion technology, slow (control) to release technology and the preparation of enteric coated preparation technology.Existing division film controlling type and matrix type tablet and capsular preparation method.
1. film controlling type capsule preparation:
1) etoposide is dissolved in acetone and the ethanol mixed solvent, adds the solid dispersion carrier, to dissolving;
2) above-mentioned solution spray is coated on the sucrose micropill;
3) film controlling type slow (control) is released material dissolves in water, spray coating is in above-mentioned 2) micropill on;
4) drying, sieve diameter are the micropill of 0.7～0.9mm;
5) the enteric solubility material is added in the entry, stir, spray coating is in above-mentioned 4) micropill on;
6) with above-mentioned 5) micropill fill in the hard capsule; Perhaps directly with above-mentioned 4) micropill fill in the enteric solubility hard capsule;
2. matrix type capsule preparation:
1) etoposide is dissolved in acetone and the ethanol mixed solvent, adds the solid dispersion carrier, to dissolving.
2) with above-mentioned solution evaporation, drying is pulverized, and crosses 80 mesh sieves.
3) with above-mentioned 2) solid dispersion and matrix type slow (control) release material and other adjuvant mix homogeneously, make soft material.
4) with above-mentioned 3) soft material, make micropill.
5) drying, sieve diameter are the micropill of 0.7～0.9mm.
6) the enteric solubility material is added in the entry, stir, spray coating is in above-mentioned 5) micropill on.
7) with above-mentioned 6) micropill fill in the hard capsule; Perhaps directly with above-mentioned 5) micropill fill in the enteric solubility hard capsule.
3. film controlling type preparation tablets:
1) etoposide is dissolved in acetone and the ethanol mixed solvent, adds the solid dispersion carrier, to dissolving.
2) with above-mentioned solution evaporation, drying is pulverized, and crosses 80 mesh sieves.
3) with above-mentioned 2) solid dispersion and other adjuvant mix homogeneously, make soft material.
4) granulate drying.
5) granulate, tabletting.
6) film controlling type slow (control) is released material dissolves in water, spray coating is in above-mentioned 5) tablet on.
7) the enteric solubility material is added in the entry, stir, spray coating is in above-mentioned 6) tablet on.
4. matrix type preparation tablets:
1) etoposide is dissolved in acetone and the ethanol mixed solvent, adds the solid dispersion carrier, to dissolving.
2) with above-mentioned solution evaporation, drying is pulverized, and crosses 80 mesh sieves.
3) with above-mentioned 2) solid dispersion and matrix type slow (control) release material and other adjuvant mix homogeneously, make soft material.
4) granulate drying.
5) granulate, tabletting.
6) the enteric solubility material is added in the entry, stir, spray coating is in above-mentioned 5) tablet on.
Confirm that through pharmacodynamic experiment, safety experiment and pharmacokinetics experimental result pharmaceutical composition clinical efficacy of the present invention is good, toxicity is low.Its tumor control rate is 73%, compares with the blank group, and suppression ratio has significant difference (p＜0.01): compare with commercially available etoposide soft capsule group, significant difference (p＜0.05) is also arranged.
The increase in life span of pharmaceutical composition group of the present invention has been compared significant difference (p＜0.01) with the blank group, comparing with commercially available etoposide soft capsule group also has significant difference (p＜0.05).
Aspect untoward reaction, pharmaceutical composition bone marrow suppression rate of the present invention is about 1/2 (32%/58%) of commercially available etoposide soft capsule.
In the pharmacokinetics experiment, the half-life of pharmaceutical composition of the present invention is about 16 hours, is 2.3 times of commercially available etoposide soft capsule (7 hours), and oral administration biaavailability is 85%, is about 2 times of commercially available etoposide soft capsule.
The specific embodiment:
Below by embodiment the present invention is elaborated, embodiment does not limit the present invention.
Embodiment 1 etoposide enteric slow (control) is released capsule (specification: 25mg)
Composition:
Etoposide 25mg
Acetone 0.05ml
Hydroxypropyl emthylcellulose E4M CR 1.5mg
Acrylic resin II 75mg
Ethanol 0.8ml
Sucrose micropill 100mg
Hydroxypropyl emthylcellulose E4M CR 3mg
Macrogol 4000 0.15mg
Distilled water 50 μ l
Aquacoat 15mg (30%)
Dibutyl sebacate 0.75mg
Distilled water 15 μ l
OPADRY
ACRYL-EZE
TM 16.8mg
Distilled water 67.2 μ l
Preparation:
1. etoposide is dissolved in acetone and the ethanol mixed solvent, slowly adds hydroxypropyl emthylcellulose and acrylic resin II, the limit edged stirs, until whole dissolvings.
2. above-mentioned solution spray is coated on the sucrose micropill.
3. hydroxypropyl emthylcellulose and Macrogol 4000 are dissolved in water, spray coating is on the micropill of above-mentioned (2).
4. Aquacoat and dibutyl sebacate are added in the entry, stir, spray coating is on the micropill of above-mentioned (3).
5. dry, sieve diameter is the micropill of 0.7～0.9mm.
6. with OPADRY
ACRYL-EZE
TMBe added in the water, make the suspension of 20% (W/V), spray coating is on the micropill of above-mentioned (5).
7. the micropill with above-mentioned (6) fills in the suitable capsule.Perhaps directly the micropill of above-mentioned (5) is filled in the suitable enteric solubility hard capsule.
Embodiment 2 etoposide enterics slow (control) are released capsule (specification: 25mg)
Composition:
Etoposide 25mg
Acetone 0.05ml
Polyethylene glycol 6000 75mg
Ethanol 0.8ml
Sucrose micropill 100mg
Hydroxypropyl emthylcellulose K4M CR 3mg
Macrogol 4000 0.15mg
Distilled water 50 μ l
EUDRAGIT
/RS?PO 10mg
EUDRAGIT
RL?PO 5mg
Pulvis Talci 2mg
Triethyl citrate 1.5mg
Ethanol 320 μ l
OPADRY
ACRYL-EZE
TM 17.7mg
Distilled water 70.8 μ l
Embodiment 3 etoposide enterics slow (control) are released capsule (specification: 50mg)
Composition:
Etoposide 50mg
Polyethylene glycol 6000 25mg
Ethyl cellulose 50mg
Acrylic resin II 100mg
Ethanol 1ml
Acetone 0.15ml
Sucrose micropill 150mg
Hydroxypropyl emthylcellulose E4M CR 5mg
Macrogol 4000 0.35mg
Distilled water 60 μ l
Aquacoat (30%) 18mg
Dibutyl sebacate 0.85mg
Distilled water 20 μ l
OPADRY
ACRYL-EZE
TM 28mg
Distilled water 112 μ l
Embodiment 4 etoposide enterics slow (control) are released capsule (specification: 25mg)
Composition:
Etoposide 25mg
Polyethylene glycol 6000 25mg
Ethyl cellulose 50mg
EUDRAGIT
L?100 100mg
Acetone 0.2ml
Ethanol 2.0ml
Microcrystalline Cellulose 60mg
Hydroxypropyl emthylcellulose E4M CR 150mg
PLASDONE
S-630 30mg
Polyvinylpyrrolidone PVP
K30(10%) an amount of
Preparation:
1. etoposide is dissolved in acetone and the ethanol mixed solvent, adds the solid dispersion carrier, to dissolving.
2. with above-mentioned solution evaporation, drying is pulverized, and crosses 80 mesh sieves.
3. above-mentioned 2 solid dispersion and matrix type slow (control) are released material and other adjuvant mix homogeneously, make soft material.
4. with above-mentioned 3 soft material, make micropill.
5. dry, sieve diameter is the micropill of 0.7～0.9mm.
6. above-mentioned 5 micropill is filled in the enteric solubility hard capsule.
Embodiment 5 etoposide enterics slow (control) are released sheet (specification: 25mg)
Composition:
Etoposide 25mg
Poloxamer F-68 0.15mg
Polyethylene glycol 6000 50mg
Polyvinylpyrrolidone PVP
K1550mg
Ethanol 1ml
Acetone 0.05ml
Lactose 25mg
Microcrystalline Cellulose 30mg
Hydroxypropyl emthylcellulose K15M CR 90mg
Polyvinylpyrrolidone PV
K30(10%) an amount of
Magnesium stearate (0.5%) is an amount of
OPADRY
ACRYL-EZE
TM 22mg
Distilled water 112 μ l
Preparation:
1. with etoposide and polyvinylpyrrolidone PVP
K15Be dissolved in acetone and the ethanol mixed solvent, poloxamer F-68 and polyethylene glycol 6000 are added hot melt, then both are mixed, stir.
2. under 50 ℃, vacuum drying is pulverized, and crosses 80 mesh sieves.
3. with polyvinylpyrrolidone PV
K30(10%) aqueous solution is a binding agent, and magnesium stearate (0.5%) is a lubricant, granulates tabletting.
4. the bag enteric film coat promptly coats OPADRY
ACRYL-EZE
TM, make weightening finish about 7%.
Embodiment 6 etoposide enterics slow (control) are released sheet (specification: 25mg)
Composition:
Etoposide 25mg
Polyethylene glycol 6000 150mg
Acetone 0.1ml
Ethanol 1.0ml
EUDRAGIT
L?100 50mg
EUDRAGIT
RL?PO 75mg
Microcrystalline Cellulose 50mg
Hydroxypropyl emthylcellulose E4M CR 125mg
Sodium alginate (1%) is an amount of
Magnesium stearate (0.5%) is an amount of
OPADRY
ACRYL-EZE
TM 7％
Embodiment 7 etoposide enterics slow (control) are released sheet (specification: 25mg)
Composition:
Etoposide 25mg
Pluromic?F68 50mg
PLASDONE
S-630 10mg
Acetone 0.1ml
Ethanol 0.8ml
Lactose 170mg
Microcrystalline Cellulose 30mg
Polyvinylpyrrolidone PVP
K30(10%) an amount of
Magnesium stearate (0.5%) is an amount of
EUDRAGIT
RS?PO 14mg
EUDRAGIT
RL?PO 6mg
Pulvis Talci 4mg
Triethyl citrate 2mg
Ethanol 340 μ l
OPADRY
ACRYL-EZE
TM 7％
Preparation:
1. etoposide is dissolved in acetone and the ethanol mixed solvent, adds the solid dispersion carrier, to dissolving.
2. with above-mentioned solution evaporation, drying is pulverized, and crosses 80 mesh sieves.
3. with above-mentioned 2 solid dispersion and other adjuvant mix homogeneously, make soft material.
4. granulate drying.
5. granulate, tabletting.
6. film controlling type slow (control) is released material dissolves in water, spray coating is on above-mentioned 5 tablet.
7. the enteric solubility material is added in the entry, stir, spray coating is on above-mentioned 6 tablet.
Embodiment 8 etoposide enterics slow (control) are released sheet (specification: 25mg)
Composition:
Etoposide 25mg
Polyethylene glycol 6000 50mg
Acetone 0.1ml
Ethanol 0.5ml
Lactose 100mg
Microcrystalline Cellulose 50mg
Hydroxypropyl emthylcellulose E10M CR 25mg
Polyvinylpyrrolidone PVP
K30(10%) an amount of
Magnesium stearate (0.5%) is an amount of
Aquacoat 25mg (30%)
Dibutyl sebacate 1.25mg
Distilled water 25 μ l
OPADRY
ACRYL-EZE
TM 7％
Embodiment 9 etoposide enterics slow (control) are released sheet (specification: 35mg)
Composition:
Etoposide 35mg
Polyethylene glycol 6000 175mg
Cetomacrogol 1000 0 175mg
Acetone 0.1ml
Ethanol 0.8ml
Microcrystalline Cellulose 100mg
L-HPC 50mg
Hydroxypropyl emthylcellulose E10M CR 165mg
Polyvinylpyrrolidone PV
K30(10%) an amount of
Magnesium stearate (0.5%) is an amount of
OPADRY
ACRYL-EZE
TM 7％
Embodiment 10 etoposide enterics slow (control) are released sheet (specification: 40mg)
Composition:
Etoposide 40mg
EUDRAGIT
L100-55 40mg
Acetone 0.15ml
Ethanol 0.6ml
Microcrystalline Cellulose 10mg
Hydroxypropyl emthylcellulose K15M CR 40mg
Polyvinylpyrrolidone PVP
K30(10%) an amount of
Magnesium stearate (0.5%) is an amount of
OPADRY
ACRYL-EZE
TM 7％
Embodiment 11 etoposide enterics slow (control) are released sheet (specification: 35mg)
Composition:
Etoposide 35mg
EUDRAGIT
L100 105mg
Acetone 0.15ml
Ethanol 1.0ml
L-HPC 50mg
EUDRAGIT
RL?PO 100mg
Hydroxypropyl emthylcellulose K4M CR 185mg
Sodium alginate (1.0%) is an amount of
Magnesium stearate (0.5%) is an amount of
OPADRY
ACRYL-EZE
TM 7％
Embodiment 12 etoposide enterics slow (control) are released sheet (specification: 35mg)
Composition:
Etoposide 35mg
Polyvinylpyrrolidone PVP
K1570mg
Acetone 0.1ml
Ethanol 0.5ml
EUDRAGIT
L100 150mg
Hydroxypropyl emthylcellulose K4M CR 20mg
Lactose 40mg
Microcrystalline Cellulose 100mg
Polyvinylpyrrolidone PVP
K30(10%) an amount of
Magnesium stearate (0.5%) is an amount of
EUDRAGIT
RS?PO 4.5mg
EUDRAGIT
RL?PO 4.5mg
Pulvis Talci 1.8mg
Triethyl citrate 0.9mg
Ethanol 175 μ l
OPADRY
ACRYL-EZE
TM 7％
Embodiment 13 pharmaceutical composition antineoplastic pharmacodynamic experiments of the present invention
1, laboratory animal: Lewis lung cancer model mice
2, the pharmaceutical composition 175mg/m2/ day of experiment medicine: embodiment 1, commercially available etoposide soft capsule 175mg/m2/ day, blank capsules 175mg/m2/ day
3, experimental technique: to mouse gavaging experiment medicine, successive administration 5 days is measured the tumor control rate of three kinds of medicines then respectively.
4, experimental result:
Tumor control rate is respectively: pharmaceutical composition group 73% of the present invention, commercially available etoposide soft capsule group 52%, blank capsules group 0.Pharmaceutical composition group of the present invention is compared with the blank capsules group, and suppression ratio has significant difference (p＜0.01); Pharmaceutical composition group of the present invention is compared with commercially available etoposide soft capsule group, and suppression ratio also has significant difference (p＜0.05).
The safety experiment of embodiment 14 pharmaceutical compositions of the present invention
1, laboratory animal: L615 Reticulocyte leukemia model mice
2, the pharmaceutical composition 175mg/m of experiment medicine: embodiment 1
2/ day,
Contrast: commercially available etoposide soft capsule 175mg/m
2/ day, blank capsules 175mg/m
2/ day
3, experimental technique: to mouse gavaging experiment medicine and reference substance, successive administration 5 days is measured increase in life span, the bone marrow suppression rate of three kinds of medicines then respectively and is carried out relevant pharmacokinetics experiment.
4, experimental result:
The increase in life span of pharmaceutical composition group of the present invention and commercially available etoposide soft capsule group has been compared significant difference (p＜0.01) with the blank capsules group, the increase in life span of pharmaceutical composition group of the present invention is compared with commercially available etoposide soft capsule group also has significant difference (p＜0.05).
Aspect untoward reaction: pharmaceutical composition bone marrow suppression rate of the present invention is about 1/2 (32%/58%) of commercially available etoposide soft capsule.
The pharmacokinetics experiment of embodiment 15 pharmaceutical compositions of the present invention
Laboratory animal and experiment medicine are with embodiment 10.
Experimental technique: to mouse gavaging experiment medicine and reference substance, successive administration 5 days is measured half-life of pharmaceutical composition of the present invention and commercially available etoposide soft capsule, calculating oral administration biaavailability then respectively.
The result: the half-life of pharmaceutical composition of the present invention is about 16 hours, is 2.3 times of commercially available etoposide soft capsule (7 hours), and oral administration biaavailability is 85%, is about 2 times of commercially available etoposide soft capsule.
Claims (7)
1. an etoposide enteric slow (control) is released the solid dispersion medicine compositions, and described pharmaceutical composition contains etoposide 5～30% (weight); Solid dispersion carrier 5～50% (weight); Slow (control) releases material 3～35% (weight); Other composition is pharmaceutically acceptable pharmaceutical adjuvant;
Described solid dispersion carrier is an acceptable water-solubility carrier pharmaceutically, or in water insoluble carrier or the enteric solubility carrier one or more;
Described water-solubility carrier is selected from polyethylene glycol 6000, Macrogol 4000, cetomacrogol 1000 0, poloxamer F-68, polyvinylpyrrolidone K15, PLASDONER S-630;
Described water insoluble carrier is selected from ethyl cellulose;
Described enteric solubility carrier is selected from acrylic resin II, EUDRAGIT L 100, EUDRAGIT RL 90, EUDRAGIT L100-55;
Described slow (control) released material and is selected from matrix type slow (control) and releases material and film controlling type and delay (control) and release material.
2. the described pharmaceutical composition of claim 1, it is hydrophilic gel matrix material that described matrix type slow (control) is released material.
3. the described pharmaceutical composition of claim 2, described hydrophilic gel matrix material is selected from hydroxypropyl emthylcellulose E4M, hydroxypropyl emthylcellulose K4M, hydroxypropyl emthylcellulose K15M, hydroxypropyl emthylcellulose E10M, sodium alginate.
4. the described pharmaceutical composition of claim 1, described film controlling type slow (control) is released material and is selected from ethyl cellulose class or polyacrylic resin.
5. the described pharmaceutical composition of claim 4, described film controlling type slow (control) is released material and is selected from Aquacoat, EUDRAGIT RS PO, EUDRAGIT RL PO, OPADRY ACRYL-EZETM.
6. the dosage form of the described pharmaceutical composition of claim 1 is tablet and hard capsule.
7. the described preparation of drug combination method of claim 1:
The film controlling type capsule:
1) etoposide is dissolved in acetone and the ethanol mixed solvent, adds the solid dispersion carrier, to dissolving;
2) above-mentioned solution spray is coated on the sucrose micropill;
3) film controlling type slow (control) is released material dissolves in water, spray coating is in above-mentioned 2) micropill on;
4) drying, sieve diameter are the micropill of 0.7～0.9mm;
5) the enteric solubility material is added in the entry, stir, spray coating is in above-mentioned 4) micropill on;
6) with above-mentioned 5) micropill fill in the hard capsule; Perhaps directly with above-mentioned 4) micropill fill in the enteric solubility hard capsule;
The matrix type capsule:
1) etoposide is dissolved in acetone and the ethanol mixed solvent, adds the solid dispersion carrier, to dissolving;
2) with above-mentioned solution evaporation, drying is pulverized, and crosses 80 mesh sieves;
3) with above-mentioned 2) solid dispersion and matrix type slow (control) release material and other adjuvant mix homogeneously, make soft material;
4) with above-mentioned 3) soft material, make micropill;
5) drying, sieve diameter are the micropill of 0.7～0.9mm;
6) the enteric solubility material is added in the entry, stir, spray coating is in above-mentioned 5) micropill on;
7) with above-mentioned 6) micropill fill in the hard capsule; Perhaps directly with above-mentioned 5) micropill fill in the enteric solubility hard capsule;
The film controlling type tablet:
1) etoposide is dissolved in acetone and the ethanol mixed solvent, adds the solid dispersion carrier, to dissolving;
2) with above-mentioned solution evaporation, drying is pulverized, and crosses 80 mesh sieves;
3) with above-mentioned 2) solid dispersion and other adjuvant mix homogeneously, make soft material;
4) granulate drying;
5) granulate, tabletting;
6) film controlling type slow (control) is released material dissolves in water, spray coating is in above-mentioned 5) tablet on;
7) the enteric solubility material is added in the entry, stir, spray coating is in above-mentioned 6) tablet on;
The matrix type tablet:
1) etoposide is dissolved in acetone and the ethanol mixed solvent, adds the solid dispersion carrier, to dissolving;
2) with above-mentioned solution evaporation, drying is pulverized, and crosses 80 mesh sieves;
3) with above-mentioned 2) solid dispersion and matrix type slow (control) release material and other adjuvant mix homogeneously, make soft material;
4) granulate drying;
5) granulate, tabletting.
6) the enteric solubility material is added in the entry, stir, spray coating is in above-mentioned 5) tablet on.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02153962 CN1204895C (en) | 2002-12-06 | 2002-12-06 | Etoposide enteric slow (controlled) release solid dispersing preparation and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02153962 CN1204895C (en) | 2002-12-06 | 2002-12-06 | Etoposide enteric slow (controlled) release solid dispersing preparation and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1478481A CN1478481A (en) | 2004-03-03 |
| CN1204895C true CN1204895C (en) | 2005-06-08 |
Family
ID=34148796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02153962 Expired - Fee Related CN1204895C (en) | 2002-12-06 | 2002-12-06 | Etoposide enteric slow (controlled) release solid dispersing preparation and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1204895C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926809B (en) * | 2009-06-19 | 2011-10-05 | 上海医药工业研究院 | Pharmaceutical preparation and preparation method thereof |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100415242C (en) * | 2005-06-07 | 2008-09-03 | 北京振东光明药物研究院 | Drop pills of vepeside and preparation process thereof |
| HUE033556T2 (en) * | 2009-07-30 | 2017-12-28 | Evonik Roehm Gmbh | Powdery or granulated composition comprising a copolymer, a dicarboxylic acid and a fatty monocarboxylic acid |
| CN103142533B (en) * | 2013-03-21 | 2014-05-21 | 青岛正大海尔制药有限公司 | Enteric coated tablet of etoposide |
| CN103211775B (en) * | 2013-03-21 | 2014-07-30 | 青岛正大海尔制药有限公司 | Dispersible tablet |
| CN103142530B (en) * | 2013-03-21 | 2014-08-20 | 青岛正大海尔制药有限公司 | Sustained-release tablet of etoposide |
| CN103142497B (en) * | 2013-03-21 | 2014-04-30 | 青岛正大海尔制药有限公司 | Enteric granule of etoposide |
| CN103142545B (en) * | 2013-03-21 | 2014-05-21 | 青岛正大海尔制药有限公司 | Enteric capsule of etoposide |
| CN106008788B (en) * | 2016-05-18 | 2017-11-07 | 连云港万泰医药辅料技术有限公司 | A kind of hypotonicity Sustained release coating materials and preparation method thereof |
| CN106924189B (en) * | 2017-04-28 | 2021-08-24 | 华南农业大学 | Tilmicosin sustained-release enteric-coated powder and preparation method and application thereof |
| CN111728949B (en) * | 2020-07-17 | 2022-10-04 | 广州帝奇医药技术有限公司 | Insoluble medicine oral sustained-release composition and preparation method thereof |
-
2002
- 2002-12-06 CN CN 02153962 patent/CN1204895C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926809B (en) * | 2009-06-19 | 2011-10-05 | 上海医药工业研究院 | Pharmaceutical preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1478481A (en) | 2004-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1222290C (en) | Novel composition and use thereof | |
| CN1229111C (en) | Sustained release preparations | |
| CN1023765C (en) | Sustained release matrix formulations | |
| CN101068534A (en) | Pharmaceutical compositions comprising levetiracetam and process for their preparation | |
| CN1230162C (en) | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent | |
| CN1149979C (en) | Medicinal composition | |
| CN1182841C (en) | New pharmaceutical formulation and preparation process | |
| CN1171587C (en) | Gamma-contained aminobutyric acid derivatives solid compositions and preparation process thereof | |
| CN1194687C (en) | Pharmaceutical formulations comprising amoxocyllin and clavulanate | |
| CN1155382C (en) | Tablet with controlled release of alfuzosine chlorydrate | |
| CN1076605C (en) | Agent for treating hepato biliary diseases | |
| CN1204895C (en) | Etoposide enteric slow (controlled) release solid dispersing preparation and its preparation method | |
| CN101036633A (en) | Enteric coated omeprazole pellets capsule and the preparing method thereof | |
| CN1444582A (en) | Heterocyclic compound, their preparation and use | |
| CN1929821A (en) | Pharmaceutical composition comprising pimobendan | |
| CN1518442A (en) | Pharmaceutical compositions comprising cyclosporin | |
| CN1407887A (en) | Oral liquid compositions | |
| CN1111507A (en) | Controlled release oxybutynin formulations | |
| CN1652752A (en) | Naltrexone hydrochloride compositions | |
| CN1159004C (en) | Swallowable tablets with high content of N-acetylcysteine | |
| CN1292696A (en) | Composition | |
| CN1684669A (en) | Compositions comprising HMG-CoA reductase inhibitor | |
| CN1165295C (en) | Controlled-release compositions of betahistine | |
| CN1823805A (en) | Ground erythromycin enteric micropill and its preparation method | |
| CN1150902C (en) | Prescription of preparing moxapride citrate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CHONGQING HUAPONT PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HUABANG PHARMACEUTICAL CO., LTD., CHONGQING Effective date: 20130217 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 400041 JIULONGPO, CHONGQING TO: 401121 YUBEI, CHONGQING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130217 Address after: 401121 Chongqing, Yubei District and the number of stars Avenue, No. 69 Patentee after: Chongqing Huapont Pharm. Co., Ltd. Address before: Four street in Chongqing city from 400041 Science Park No. 55 Patentee before: Huabang Pharmaceutical Co., Ltd., Chongqing |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050608 Termination date: 20161206 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |